72 results about "Postoperative monitoring" patented technology

A method for the early diagnosis of breast, lung, pancreatic and colon growths and cancers as well as conditions associated with donor and recipient organ transplants, both before and after transplantation to identify and allow treatment of possible transplanted organ rejection and other disease conditions related and unrelated to the transplantation, compares the gene expression patterns from a patient's peripheral blood monocytes-lymphocyte's gene system with either the similar gene expression patterns of a normal person, or with the similar gene expression patterns of a person known to have the condition being screened for. Differences between the patient's gene expression patterns for particular genes and the normal patterns indicates the presence of the condition with the number of differences indicating the probability of the condition. Similarities between the patient's gene expression patterns for those particular genes and the patterns of a person known to have the condition indicates the presence of the condition with the number of similarities indicating the probability of the condition. For example, particular genes for use in identifying pancreatic cancer are disclosed.

The present invention is directed to a system and method for postoperative monitoring of the condition of a tissue or organ utilizing sensors that may be embedded in various types of surgical drains. The system is comprised of a probe and a monitoring unit. The probe may include a surgical drain with fluid draining channels housing one or more sensors to measure various parameters of the adjacent tissue. The monitoring unit which controls the sensors of the probe may include a processor to process, record and display the measured parameters. This system may be valuable for monitoring transplanted organs and tissue grafts during the critical postoperative period when most of the clinical complications, such as vascular thrombosis, may occur.

An imaging system consisting of a cell-phone with camera as the detection part of an optical train which includes other components. Optionally, an illumination system to create controlled contrast in the sample. Uses include but are not limited to disease diagnosis, symptom analysis, and post-procedure monitoring, and other applications to humans, animals, and plants.

The invention relates to a urine-based method and kit for diagnosing the relapse risk of a bladder cancer patient. The invention discloses two methylation-sensitive genes, namely an LMX1A gene and a VAX1 gene. A urine sample is kept before the operation of a detected bladder cancer patient, and the specific CpG sites of the genes are subjected to high methylation among people who are determined to suffer from a relapse in the follow-up visit process. Thus, the two genes can be used as biological markers for the relapse of bladder cancer. The invention can be used as the basis for designing a kit for prognosing and diagnosing the relapse of bladder cancer, and is applicable to the prognosis detection of bladder cancer in hospital, the postoperative follow-up visit and the postoperative monitoring of the community health center on people subjected to bladder cancer operation.

A method for the early diagnosis of breast, lung, pancreatic and colon growths and cancers as well as conditions associated with donor and recipient organ transplants, both before and after transplantation to identify and allow treatment of possible transplanted organ rejection and other disease conditions related and unrelated to the transplantation, compares the gene expression patterns from a patient's peripheral blood monocytes-lymphocyte's gene system with either the similar gene expression patterns of a normal person, or with the similar gene expression patterns of a person known to have the condition being screened for. Differences between the patient's gene expression patterns for particular genes and the normal patterns indicates the presence of the condition with the number of differences indicating the probability of the condition. Similarities between the patient's gene expression patterns for those particular genes and the patterns of a person known to have the condition indicates the presence of the condition with the number of similarities indicating the probability of the condition. For example, particular genes for use in identifying pancreatic cancer are disclosed.

The invention relates to a DNA nano-origami structure constructed by rolling circle amplification technology and DNA origami, at the same time utilizes fluorescent dye DAPI with DNA double-strand binding properties and cell membrane penetration properties to label and track the DNA nano-origami structure, thus realizing real-time monitoring and simulation of the drug loading and sustained release process of the DNA nano-origami structure as a drug carrier. And the method also can be applied as a new fluorescent quantitative analysis method to biomolecular detection, like tumor early detection, postoperative monitoring and evaluation, cell imaging and other fields.

The invention provides new application of galectin-4 protein in preparation of a huge liver cancer postoperative prognostic evaluation kit. Via wide and thorough researches, an inventor firstly discovers that detection of the relative expression level of the galectin-4 protein in a huge liver cancer tissue in an immunohistochemistry way can judge the risk of liver cancer recrudesce transfer of a huge liver cancer patient. The application has the main benefits as follows: the application of the galectin-4 protein in the preparation of the huge liver cancer postoperative prognostic evaluation kit, provided by the invention, points out that the galectin-4 protein can be used for preparing a protein molecular marker for prognosis of the huge liver cancer patient, and has important significance of guiding the huge liver cancer patient's postoperative monitoring and sequential treatment.

The invention relates to the field of medical examination, and particularly relates to a sample dilution composition for detecting a sugar antigen 72-4, a detection reagent and a kit containing the detection reagent. The kit mainly comprises a magnetic particle suspension coated with a CA72-4 antibody, an enzyme conjugate, a sample diluent and a calibrator. The sample dilution composition can be used for auxiliary diagnosis and postoperative monitoring of tumor diseases such as gastric cancer, ovarian cancer, colorectal cancer, pancreatic cancer and cervical cancer. The kit is short in detection time, and the time of an inspector is greatly saved; the kit adopts a double-antibody sandwich method, is wide in linear range and high in clinical practicability; the kit adopts the specific sample diluent, so that the difference between new and old samples can be eliminated, false positive interference caused by HAMA is effectively reduced, and the detection accuracy of CA72-4 is greatly improved; and the kit adopts a two-step method, so that the risk of HOOK in clinical practice is reduced.

The invention provides the application of the TCP1 protein in the preparation of a breast cancer postoperative prognosis evaluation kit, a breast cancer prognosis evaluation kit and a method. The present invention uses an immunohistochemical method to detect the relative expression of TCP1 protein in breast cancer tissue, so as to judge the risk of breast cancer recurrence and metastasis in breast cancer patients. The beneficial effects of the present invention are mainly reflected in: the present invention provides the application of TCP1 protein in the preparation of breast cancer postoperative prognosis assessment kit, suggesting that the protein can be used to prepare protein molecular markers for judging the prognosis of breast cancer patients. Postoperative monitoring and sequential treatment also have important guiding significance.

The invention discloses an ascending aorta covered stent and conveying system assembly and a using method thereof, belongs to the technical field of minimally invasive surgery, and aims to solve the problems that in the prior art, minimally invasive surgery is difficult to use in ascending aorta treatment and the like. The ascending aorta covered stent and conveying system assembly comprises a stent conveyor and a covered stent. The stent conveyor comprises an outer sheath tube, an adjustable bent tube, a single-cavity inner middle tube, a single-cavity inner tube, a flexible TIP head, a chronic dilator and an adjusting handle. The covered stent comprises a proximal end bare crown stent and a telecentric end covered stent which are connected with each other. According to the ascending aorta covered stent and conveying system assembly and the using method thereof, the problem that the ascending aorta dissection is not suitable for minimally invasive surgery is solved, the death rate and the complication occurrence rate in the surgery period are reduced, the needed hospitalization and postoperative monitoring time is shorter, and the outer sheath tube has enough axial and radial supporting force and compliance.

The invention discloses a gastrointestinal cancer postoperative cancer cell monitor based on big data, the gastrointestinal cancer postoperative cancer cell monitor comprises a left headset, a right headset, a microprocessor and an amplification circuit, magnetic sensors are arranged in the left headset and the right headset, and a magnetic induction cycle is formed between the two magnetic sensors; the invention further provides a use method of the gastrointestinal cancer postoperative cancer cell monitor based on the big data. The use method comprises the following steps: S1, a monitoring process; S2, postoperative monitoring; S3, information processing; and S4, comparing and judging. The system is reasonable in structure, the monitoring headset is arranged, electromagnetic waves are spread in a human body, the health state and the cell map of human cells are received, the cell state is analyzed and compared through an existing cell map, and information received by postoperative cells of a patient with gastrointestinal cancer is analyzed and compared from the microcellular level. The spectrum of postoperative cells of gastrointestinal cancer patients on the cellular level is analyzed and examined, and the defects existing in macroscopic examination are overcome.

The invention belongs to the biotech field, relates to an application of an Shp2 protein, and concretely relates to an application of the Shp2 protein in preparation of a liver cancer prognosis evaluation kit. The relative Shp2 protein expression level of a tumor tissue to a tissue adjacent to the tumor is determined through utilizing an immunohistochemical technology, microscope shooting and computer image processing software, and postoperative follow-up information is combined to determine that the relative Shp2 protein expression level is related with the hepatocellular carcinoma patient prognosis after the operation, so the Shp2 protein can be used for preparing a protein molecule maker for determining the liver cancer patient, and is of great guiding significance to the postoperative monitoring and sequential treatment of hepatocellular carcinoma patients.

The invention relates to the technical field of medical biological detection and provides novel uses of WDR1, NMI and LIN28 proteins, particularly an application in preparation of a kit for assessingbrain glioblastoma prognosis. The invention further provides a kit and detection method performing brain glioblastoma prognosis assessing through quantitative detection of the WDR1, NMI and LIN28 proteins by adopting an immunohistochemical method. Expression levels of the WDR1, NMI and LIN28 proteins in brain glioblastoma tissues are measured by utilizing an immunohistochemical technique and system scoring, and it is determined that the expression levels of the WDR1, NMI and LIN28 proteins are related with prognosis of patients with brain glioblastoma after operations by combination with postoperative follow-up observation information. The combination of the WDR1, NMI and LIN28 proteins can be used for preparing a protein molecular marker for determining prognosis of patients with brain glioblastoma, and is of great directive significance for brain glioblastoma molecular subtyping, postoperative monitoring of patients and sequential therapy.

The invention belongs to the technical field of medical treatment, in particular to a postoperative monitoring cover for the for ophthalmology department. The postoperative monitoring cover comprisesa first upper clamping plate and a second upper clamping plate. Lower clamping plates are connected to the lower surfaces of the first upper clamping plate and the second upper clamping plate in a clamped mode. Cotton cloth protection pockets are connected to the lower surfaces of the first upper clamping plate and lower clamping plates in a clamped mode; a sponge pad is sewed in each cotton clothprotection pocket; a hook-and-loop fastener rough surface is sewed on the lower surface of each cotton cloth protection pocket; the sponge cushions can perform buffer protection between the lower clamping plates and the eyes of a patient; meanwhile, a hook-and-loop fastener rough surface and a hook-and-loop fastener hook surface are arranged between each cotton cloth protection pocket and gauze absorbent cotton; therefore, the gauze absorbent cotton can be conveniently adhered to the lower surface of each cotton cloth protection pocket for use; gauze absorbent cotton can be conveniently driven by the first upper clamping plate and lower clamping plate to be attached to the eyes of the patient for medicine application nursing, the gauze absorbent cotton is arranged to be bonded to the lower surface of each cotton cloth protection pocket, and therefore medicine replacement can be conveniently conducted after the gauze absorbent cotton is used.

The invention provides the application of the CCBE1 protein in the preparation of a kit for evaluating the prognosis of rectal cancer, the kit and the method for evaluating the prognosis of rectal cancer. The present invention detects the relative expression level of CCBE1 protein in rectal cancer tissue by immunohistochemical method, so as to judge the risk of rectal cancer recurrence and metastasis in rectal cancer patients. The beneficial effects of the present invention are mainly reflected in: the present invention provides the application of CCBE1 protein in the preparation of the postoperative prognosis assessment kit for rectal cancer, suggesting that CCBE1 protein can be used to prepare protein molecular markers for judging the prognosis of rectal cancer patients. Postoperative monitoring and sequential treatment also have important guiding significance.

The invention relates to the technical field of biotechnology, in particular to a lung cancer detection kit which takes miR-21 and miR-205 in serum as markers and is used for lung cancer screening and postoperative monitoring. The miR-21 and miR-205 in serum / blood plasma are selected to jointly serve as lung cancer markers, and the lung cancer diagnostic kit which has rapidness and convenience in detection, is high in accuracy and can be used for achieving lung cancer early screening and prognostic auxiliary diagnoses is developed through a qRT-PCR method. The kit has rapidness and convenience in detection and is high in detection sensitivity and specificity and low in cost, can meet the early screening and prognosis judgment detection requirements of a majority of cancer patients, is extremely wide in application range, and is high in accuracy according to clinical verification prediction. The detection sensitivity of the kit in distinguishing lung cancer samples and samples of able-bodied persons is 96.3%, and the specificity is 89.7%.

The invention provides application of TPM2 proteins to preparation of a rectal cancer prognosis evaluation kit, the rectal cancer prognosis evaluation kit and a rectal cancer prognosis evaluation method. The relative expression quantity of the TPM2 proteins in rectal cancer tissues is detected through an immunohistochemical method to judge the risks that rectal cancer patients suffer from relapseand metastasis. The application prompts that the TPM2 proteins can be also used for preparing protein molecule markers for judging prognosis of the rectal cancer patients and is of great guiding significance to postoperative monitoring and sequential therapy of the rectal cancer patients.

The invention provides a non-small cell lung cancer brain metastases prediction device which consists of five concentric circles and a pointer with an arrow, wherein the five concentric circles and the pointer are fixed through metal rivets by sharing the same center to form a compass shape; postoperative pathological parameters of tumor patients, such as tumor types, differentiation degree and lymph gland states, are respectively marked on the concentric circles. The risk of non-small cell lung cancer brain metastases is evaluated by utilizing the state of a tumor marker NSE. The device is reasonable in design, is displayed in an intuitive compass form, and can be used for guiding a clinicist to estimate the prognostic risk of brain metastases of the patient, perform early interventional treatment on a patient with high risk and select an optimal comprehensive treatment scheme for the patient; meanwhile, the postoperative monitoring strategy can be perfected, the reexamination frequency is increased, the brain imaging check is emphasized, and the device provides help for timely discovering the brain metastases.

The invention relates to application of cyclin protein G1. Relative expression quantity of the cyclin protein G1 between tumor tissues and tissue adjacent to tumor is determined by utilizing an immunohistochemistry technology, picture taking by a microscope and computer image processing software, correlation between the relative expression quantity of the cyclin protein G1 and prognosis of postoperative patient with hepatocellular carcinoma is determined by combining postoperative follow-up visit information, the cyclin protein G1 can be applied to preparation of a protein molecule maker for judging the prognosis of the patient with liver cancer and has importance directive significance for postoperative monitoring and sequential treatment for patients with hepatocellular carcinoma.

An application of polypeptide mark object in large intestine cancer detection includes knowing that correlation polypeptide content in serum specimen of large intestine cancer is obviously raised, using surface intensified laser de-absorption ionization flying time mass analyzer to determine correlation polypeptide content in serum specimen of patient for confirming whether detected patient is large intestine cancer patient or not.

The invention discloses application of CHKA proteins in preparing a kit for prognostic evaluation of liver cancer. The expression amount of the CHKA proteins in the tumor tissue is determined by means of an immunohistochemical technique, microscope photographs and computer image processing software. The method for determining the expression amount of the CHKA can be used for judging the prognosis effect of the postoperative liver cancer patient, and provides important guidance for the postoperative monitoring and the sequential treatment of liver cancer patients. Moreover, the invention further discloses a kit for the prognostic evaluation of liver cancer and the method.

The invention provides a visual monodisperse embolism microsphere with internal radiation therapy performance, the embolism microsphere is composed of a polymer microsphere and radionuclide, the radionuclide is connected to the polymer microsphere through a chemical bond, and the base material of the polymer microsphere is a photo-initiated polymerization degradable polymer. The radionuclide is iodine-131, iodine-129, iodine-125, holmium-166, lutetium-177, rhenium-188 or indium-111. The particle size of the embolism microsphere is 20-100 [mu] m, and the variable coefficient of the particle size of the embolism microsphere does not exceed 5%. Degradability and visualization of the embolism microspheres in vivo are achieved at the same time, the monodispersity of the embolism microspheres is improved, the possibility of mistaken embolism can be reduced, and postoperative monitoring and evaluation are facilitated. The invention also provides a preparation method of the embolism microsphere. The method can simplify the preparation process, reduce the production cost and improve the production efficiency.

The invention belongs to the biotech field, relates to an application of an Shp2 protein, and concretely relates to an application of the Shp2 protein in preparation of a liver cancer prognosis evaluation kit. The relative Shp2 protein expression level of a tumor tissue to a tissue adjacent to the tumor is determined through utilizing an immunohistochemical technology, microscope shooting and computer image processing software, and postoperative follow-up information is combined to determine that the relative Shp2 protein expression level is related with the hepatocellular carcinoma patient prognosis after the operation, so the Shp2 protein can be used for preparing a protein molecule maker for determining the liver cancer patient, and is of great guiding significance to the postoperative monitoring and sequential treatment of hepatocellular carcinoma patients.

The invention relates to a method, software, and device 300 used to determine a size or size range 260 for an aperture in the interatrial septum of a heart. The invention relates to software 200 with a learning model 310 which helps a clinician select a surgical shunt size for a patient, monitoring the patient post operatively, and for making shunt modification recommendations, based on specific and aggregate patient data.

The invention discloses a monitoring device applied to lower limb postoperative monitoring and a monitoring method thereof. The monitoring device comprises an information collection module, a plurality of sensors, foot rings, a data processing center and a protection part. The monitoring device comprehensively monitors the foot condition through a pressure sensor and a flexible deformation sensor,and can accurately analyze the motion state of the lower limbs so as to judge the motion state of the human body, namely judging whether the human body falls down or not; wherein the foot ring servesas a relay station and is close to the information collection module, the signals are stable, the power and the size of the foot ring are allowed to be increased due to the technical indexes of the foot ring, and long-distance signal transmission and accurate protection part control are facilitated. The device is applied to the field of medical supplies.

The invention discloses heart disease post-operation real-time monitoring and early warning equipment which is internally provided with a post-operation monitoring and early warning system and a post-operation rehabilitation guidance system, wherein the postoperative monitoring and early warning system is composed of a registration and login module, a sign data acquisition module, a sign data monitoring module, a sign data analysis module, a sign early warning module and a wireless transmission module, and the postoperative rehabilitation guidance system is composed of a postoperative guidance module, a rehabilitation supervision module and a review diagnosis module. According to the monitoring and early warning equipment, various physical sign data of a patient are detected through the postoperative monitoring and early warning system, real-time remote early warning can be achieved, so that postoperative risks are reduced, meanwhile, postoperative rehabilitation treatment is guided and supervised through the postoperative rehabilitation guiding system, and the rehabilitation supervision module is provided with a diet assisting unit and a medicine assisting unit; auxiliary guidance is carried out on early-stage, middle-stage and later-stage diet of a patient, and the medicine auxiliary unit assists medicine treatment according to physical sign data of the patient and helps the patient to reduce medicine dependence.

The invention discloses a breast cancer cell postoperative monitor based on big data, the breast cancer cell postoperative monitor comprises a left magnetic sensor, a right magnetic sensor, a signal generator, an amplifier microprocessor and a signal resonator, and a memory is arranged in the microprocessor. The invention further provides a use method of the breast cancer cell postoperative monitor based on big data. The method comprises the following steps: S1, establishing a database; S2, postoperative monitoring; S3, pulse monitoring; S4, performing atlas analysis; and S5, synchronizing the data. The monitoring headset is arranged, electromagnetic waves are transmitted in a human body, the health state and the cell map of human cells are received, the cell state is analyzed and compared through an existing cell map, and rapid analysis and monitoring of the in-vivo cell state of a patient after operation are achieved; and the time consumption in the detection process and the secondary injury to the affected part of the patient due to the traditional mode are avoided, and the influence on the postoperative recovery of the patient is avoided.

The invention belongs to the technical field of biology. According to the invention, the protein expression index of HNF4 (hepatocyte nuclear factor 4) alpha proteins in liver cancer tissues is detected by an immunohistochemical method, so that the distant metastasis risk and the postoperative condition of a liver cancer patient can be judged. The invention provides an application of the HNF4 alpha proteins to preparation of a liver cancer prognosis evaluation kit. According to the application, the HNF4 alpha proteins are used as protein molecular markers for judging the prognosis condition of the liver cancer patient, so that the application has a guiding significance on postoperative monitoring and sequential treatment of the liver cancer patient.

The invention provides a new application of DDX20 in preparation of a rectal cancer postoperative prognosis evaluation kit. The inventor discovers for the first time that the risk of rectal cancer recurrence and metastasis of a rectal cancer patient can be determined by detecting the relative expression quantity of DDX20 in rectal cancer tissues by adopting an immunohistochemical method. The application of DDX20 in preparation of the rectal cancer postoperative prognosis evaluation kit indicates that the protein can be used for preparing a protein molecular marker for determining the prognosis of the rectal cancer patient and has the important guiding significance for postoperative monitoring and sequential treatment of the rectal cancer patient.